2017 ACR/ARHP Annual Meeting

November 3-8, 2017. San Diego, CA.

View by Number View by Title View Sessions

View by Date

Tuesday, November 7, 2017

2:30PM-4:00PM: Abstract Number: 2806

Integrated Longitudinal Analysis Increases Precision and Reduces Bias: A Comparative 5-Year Analysis in the DESIR Cohort

Spondyloarthropathies and Psoriatic Arthritis – Clinical Aspects and Treatment III

2:30PM-4:00PM: Abstract Number: 2813

Interferon-Induced APOL1 over-Expression Causes Autophagic Dysfunction and Mitochondrial Stress in Risk Variant-Carrying Endothelial Cells

Systemic Lupus Erythematosus – Human Etiology and Pathogenesis I

2:30PM-4:00PM: Abstract Number: 2814

Interferon-β Production By B Cells Promotes B Cell Survival and Is Strongly Associated with Active Disease in African Americans with SLE

Systemic Lupus Erythematosus – Human Etiology and Pathogenesis I

2:30PM-4:00PM: Abstract Number: 2793

Joint Location-Specific JAK-STAT Signaling in Rheumatoid Arthritis (RA) Fibroblast-like Synoviocytes (FLS)

Rheumatoid Arthritis – Human Etiology and Pathogenesis I

2:30PM-4:00PM: Abstract Number: 2805

Juvenile-Onset Ankylosing Spondylitis Has a Lower Rate of Radiographic Progression Than Adult-Onset Ankylosing Spondylitis

Spondyloarthropathies and Psoriatic Arthritis – Clinical Aspects and Treatment III

2:30PM-4:00PM: Abstract Number: 2800

Long-Term Safety and Efficacy of Biosimilar Infliximab (CT-P13) after Switching from Originator Infliximab: Results from the 26-Week Open Label Extension of a Randomized Norwegian Trial

Rheumatoid Arthritis – Small Molecules, Biologics and Gene Therapy III: Biosimilars Therapy

2:30PM-4:00PM: Abstract Number: 2808

Longitudinal Assessment of Cognitive Function in SLE: Identification of Trajectories

Systemic Lupus Erythematosus – Clinical Aspects and Treatment IV: Neuropsychiatric Disease and Health Economics

2:30PM-4:00PM: Abstract Number: 2783

Medications Associated with Osteoporotic Fracture Risk in Patients with Rheumatoid Arthritis

Rheumatoid Arthritis – Clinical Aspects IV: Medications and Risk

2:30PM-4:00PM: Abstract Number: 2763

mTORC1 Blockade with Rapamycin and N-Acetylcysteine Reduces Anti-Phospholipid Antibody Levels in Controlled Clinical Trials of Patients with SLE

Antiphospholipid Syndrome

2:30PM-4:00PM: Abstract Number: 2771

NOMID-Associated Complications in Mice Are Prevented By CDD-450, a Small Molecule Inhibitor of the Mitogen-Activated Protein Kinase-Activated Protein Kinase 2 (MK2) Pathway

Innate Immunity and Rheumatic Disease

2:30PM-4:00PM: Abstract Number: 2815

Pathological Roles By Siglec and Type I Interferons for the Development of Autoimmune Congenital Heart Block

Systemic Lupus Erythematosus – Human Etiology and Pathogenesis I

2:30PM-4:00PM: Abstract Number: 2782

Patient Beliefs and Preference to Initiate a Proposed Medication in Rheumatoid Arthritis

Patient Outcomes, Preferences, and Attitudes II

2:30PM-4:00PM: Abstract Number: 2766

Physical Therapy Vs. Internet-Based Exercise Training for Patients with Knee Osteoarthritis: Results of a Randomized Controlled Trial

ARHP Rehabilitation Science

2:30PM-4:00PM: Abstract Number: 2776

Plasmacytoid Dendritic Cells in Systemic Fibrosis: Pathogenic Role in Bleomycin-Induced Fibrosis Model and Correlation with Disease in Patients with Systemic Sclerosis

Innate Immunity and Rheumatic Disease

2:30PM-4:00PM: Abstract Number: 2816

Prediction of Connective Tissue Disease in an at-Risk Cohort Using a Novel Interferon Stimulated Gene Expression Score

Systemic Lupus Erythematosus – Human Etiology and Pathogenesis I

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].